Findings From a Randomized Controlled Trial of Fecal Transplantation for Patients With Ulcerative Colitis.
By N. Rossen, S. Fuentes, Mirjam van der Spek, J. Tijssen, Jorn H. A. Hartman, A. Duflou, M. Löwenberg, G. R. van den Brink, E. Mathus-Vliegen, W. D. de Vos and 3 more. Gastroenterology, 2015
923 citations recorded by the source corpus.
Subfields: Gastroenterology, Infectious Diseases, Molecular Biology
View Paper: https://www.semanticscholar.org/paper/0360024eda5d7d506fec511e55fd193f77f23801
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Gastroenterology
In Molecular Biology
Citations in the corpus
- Alteration of Gut Microbiota in Inflammatory Bowel Disease (IBD): Cause or Consequence? IBD Treatment Targeting the Gut Microbiome (2019, background): “For example, a randomized UC trial reported that no significant differences were found in recipient patients who were treated with fecal transplants obtained from healthy donors [262].”
- Effect of Fecal Microbiota Transplantation on 8-Week Remission in Patients With Ulcerative Colitis: A Randomized Clinical Trial (2019, neutral): “Endoscopic remissiong 4/38 (11) 0/35 (0) 11 (−1 to 27) NAh .”
- Factors affecting the composition of the gut microbiota, and its modulation (2019, positive): “In the succeeding years, the use of FMT focused on the treatment of CDI and rCDI with a cure rate of 87–90% (Kassam et al., 2012; Van Nood et al., 2013; Cammarota, Ianiro & Gasbarrini, 2014; Rossen et al., 2015).”
- The gut microbiota and host health: a new clinical frontier (2015, background): “76 A second trial, in which patients with UC were randomised to weekly faecal enemas from healthy donors or placebo enemas for 6 weeks, demonstrated remission in a greater percentage of patients given FMT compared with the control group (given water enema).”